Biovica International Ab Class B · OMXSTO:BIOVIC_B
Biovica International Ab Class B — Q2 2024 Earnings Presentation
30 slides from Biovica International Ab Class B's earnings presentation, Nov 28, 2023
Slide 1: Biovica International AB
©2023 Biovica International AB
Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: Q2 Interim Report Presenters
Q2 Interim Report Presenters Anders Rylander CEO Warren Cresswell President Biovica Americas Henrik Winther SVP Business Development Anders Morén CFO 3 ©2023 Biovica International AB
Slide 4: Agenda
Agenda Biovica introduction Q2 Highlights US Update Pharma Services Financial Update Summary and Q&A ©2023 Biovica International AB – Proprietary and Confidential. ©2023 All rights reserved. Biovica International AB
Slide 5: Q&A Session
Q&A Session ©2023 5 Biovica International AB
Slide 6: Biovica Introduction
Biovica Introduction ©2023 Biovica International AB
Slide 7: DiviTum TKa
DiviTum® TKa An early indicator of cancer treatment effectiveness + References: https://divitum.com/knowledge-hub/clinical-evidence/ DiviTum® TKa cell proliferation provides quicker evaluation of cancer treatment efficacy. ©2023 Biovica International AB
Slide 8: Validated by a wealth of scientific evidence
Validated by a wealth of scientific evidence 30+ published and peer-reviewed articles Cancer Area Patients Nr. of studies Strong evidence supporting the use of Breast Cancer 3,039 14 DiviTum® TKa as a clinical biomarker Gastrointestinal 713 4 of CDK4/6i response Malignant Melanoma 86 2 Collaboration
Slide 9: Strategically designed launch plan ensures growth
Strategically designed launch plan ensures growth ©2023 Biovica International AB
Slide 10: Q2 Highlights
Q2 Highlights 10 ©2023 Biovica International AB
Slide 11: Q2 2023/2024 Highlights
Q2 2023/2024 Highlights Significant events during the Q2 August-October • US & Clinical • Biovica signs 3 direct bill agreements in US • DiviTum® TKa to pursue Gap-fill process for CMS pricing decision • Biovica receives CAP Accreditation for its CLIA Laboratory • Biovica announces the start of a Di
Slide 12: Axlab new Commercial Partnership for the Nordics
Axlab new Commercial Partnership for the Nordics – increases sales push from Jan 1st, 2024 Axlab, a fast-growing company specializing in cancer Dx selling to all cancer centers in Denmark. Specialized in cancer diagnostics The contract opens for 6%TAM in with a deep network in oncology in MBC (EU-5
Slide 13: US Update
US Update 13 ©2023 Biovica International AB
Slide 14: We Continue to Execute our US Strategy
We Continue to Execute our US Strategy Medicare Pricing Hospital Contracts Regulatory Progress Clinical Trials Oncologists’ Feedback ©2023 Biovica International AB
Slide 15: Medicare Pricing
Medicare Pricing July 2023 – Proprietary Laboratory Analyses (PLA) code assigned by the AMA July 2023 - CMS subcommittee voted in favor of a Crosswalk payment methodology for DiviTum® TKa Sep 2023 – CMS issued a preliminary decision to follow the Gapfill payment methodology Oct 2023 – Biovica provid
Slide 16: Hospital Contracts Cover ~50 Hospitals
Hospital Contracts Cover ~50 Hospitals 3 Contracts Executed in Q2 Biovica signs US agreement Biovica signs second Biovica signs agreement for with leading healthcare agreement with leading US DiviTum TKa with world provider in Arizona healthcare provider renown cancer clinic 2023-09-19 09:00 2023-09
Slide 17: Certification, Credentialling, Accreditation & Licensing
Certification, Credentialling, Accreditation & Licensing Mar 2023 H2 2024 Feb 2023 Oct 2023 ©2023 Biovica International AB
Slide 18: Prospective Interventional Clinical Trials
Prospective Interventional Clinical Trials Drug-to-Drug Interaction and Dose Reduction CDK4/6 Inhibition in HR+ MBC Recruiting patients Real-Time Biomarker of Tumor Response to CDK4/6 Inhibition in HR+ MBC Abstracts have been submitted to SABCS in Dec 2023 TK IMPACT Trial Recruiting patients Biomark
Slide 19: Feedback From Medical Oncologists
Feedback From Medical Oncologists DiviTum TKa interest, utilization and clinical utility continues to expand with targeted medical oncologists, KOLs and institutions Providing Confidence Early Determination Personalized Therapy “Receiving a DiviTum TKa “From baseline to C1D15, a “Providing patients
Slide 20: Pharma Update
Pharma Update 20 ©2023 Biovica International AB
Slide 21: The Pharma Services & Collaboration Strategy
The Pharma Services & Collaboration Strategy - continues its strong progress with new agreements and increased sales! 1. TESA 2. MSA 3. CDx Collaboration 4. CDx Product Technical Evaluation Master Service CDx Development CDx product on the market Service Agreement Agreement Collaboration (Revenues d
Slide 22: Q2 Project Portfolio Highlights
Q2 Project Portfolio Highlights “I can’t understand why we haven’t used your • 35% organic growth (revenue) from Q1 to Q2 biomarker before.” -TIER-1 pharma based in Europe • 130% organic growth (revenue) from Q2 last FY to Q2 FY23/24 • Increased interest (service and collaboration) from TIER-1 oncol
Slide 23: Financial Update
Financial Update 23 ©2023 Biovica International AB
Slide 24: Q2 – Accumulated Net Sales
Q2 – Accumulated Net Sales 5 000 Net Sales for the 2:nd Quarter 4 500 4 316 • SEK 2,6M (0,96M) 4 000 3 500 Net Sales YTD Q2 3 000 • SEK 4,3M (1,5M) 2 500 2 000 1 754 Sales mainly coming from Pharma 1 506 1 500 Services 1 000 545 500 - Q1 Q2 Q3 Q4 2022/2023 2023/2024 ©2023 Biovica International AB –
Slide 25: Q2 - Cash flow development
Q2 - Cash flow development Q3 22/23 Q4 22/23 Q1 23/24 Q2 23/24 Operating cash flow before change 10 in Working Capital -24,5 MSEK 5 Change in Working Capital -5 -3,9MSEK - 10 - 15 Total Operating Cash Flow - 20 -28,3MSEK - 25 - 30 - 35 - 40 - 45 Change in Working Capital Operating Cash flow before c
Slide 26: Q2 Report Cash Position SEK Millions and Headcount
Q2 Report Cash Position SEK Millions and Headcount 160 Cash Balance Q2 SEK 46,9M 140 Total Headcount end of October: • 37 (27) which of female 18(13) 120 • SE 24 (22) US 13 (5) 100 80 60 40 20 - Q1 Q2 Q3 Q4 Cash 2022/2023 Cash 2023/2024 ©2023 Biovica International AB – Proprietary and Confidential.
Slide 27: Summary & QA
Summary & QA ©2023 27 Biovica International AB
Slide 28: Summary & Targets
Summary & Targets Targets: Measures cell proliferation from a simple blood sample FY23/24 DiviTum® TKa addresses an important clinical unmet need • ≥10 Hospital agreements in US Supported by cancer KOLs and scientific collaborators • ≥4 Commercial Agreements in Europe globally • ≥10 MSEK revenues Ma
Slide 29: Biovica International AB
29 ©2023 Biovica International AB
Slide 30: Biovica International AB
30 ©2023 Biovica International AB
Biovica International — Q2 2024 Earnings Presentation on 6ix